Cargando…

Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial

Electroconvulsive therapy (ECT) is one of the therapeutic opportunities for patients with psychological disorders when they may decline to take medication. We sought to systematically compare the anesthetic efficacy of ketamine, propofol, and dexmedetomidine for electroconvulsive therapy in treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Modir, Hesameddin, Mahmoodiyeh, Behnam, Shayganfard, Mehran, Abdus, Ayda, Almasi-Hashiani, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979203/
https://www.ncbi.nlm.nih.gov/pubmed/36571375
http://dx.doi.org/10.4103/2045-9912.350860
_version_ 1784899678144299008
author Modir, Hesameddin
Mahmoodiyeh, Behnam
Shayganfard, Mehran
Abdus, Ayda
Almasi-Hashiani, Amir
author_facet Modir, Hesameddin
Mahmoodiyeh, Behnam
Shayganfard, Mehran
Abdus, Ayda
Almasi-Hashiani, Amir
author_sort Modir, Hesameddin
collection PubMed
description Electroconvulsive therapy (ECT) is one of the therapeutic opportunities for patients with psychological disorders when they may decline to take medication. We sought to systematically compare the anesthetic efficacy of ketamine, propofol, and dexmedetomidine for electroconvulsive therapy in treatment-resistant major depressive disorder patients. This double-blind trial enrolled treatment-resistant major depressive disorder patients (n = 85) who had been hospitalized for ECT in the Amir Kabir Hospital’s psychiatric ward (Arak, Iran). The ketamine, propofol, and dexmedetomidine groups received a dose of 0.2 μg/kg ketamine, 1.5 mg/kg propofol, and 0.8 mg/kg dexmedetomidine, respectively. In all intervention groups, 10 mL of interventional drugs was injected intravenously for 10 minutes, and in the placebo group, 10 mL of normal saline was given over the same period. The dexmedetomidine group’s blood pressure was revealed comparatively lower at all times. Dexmedetomidine-treated patients showed their marked satisfaction, while those treated with propofol had shorter recovery time, shorter seizure duration, and shorter time to achieve an Aldrete score of 9–10 and increased relaxation, and next dexmedetomidine produced deeper relaxation. Propofol could shorten recovery time and seizure duration, and enhance relaxation, while dexmedetomidine was associated with higher patient satisfaction. Considering that any anesthetic which does not shorten seizure duration may serve efficiently for ECT and that ketamine-treated patients had more prolonged seizure duration, the preferred drug can hence be considered from various angles, thereby offering anesthetic agents with highly favorable efficacy in treatment-resistant major depressive disorder patients needing ECT. The drug choice thus depends on physical conditions, underlying diseases, and psychiatrist consultation.
format Online
Article
Text
id pubmed-9979203
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-99792032023-03-03 Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial Modir, Hesameddin Mahmoodiyeh, Behnam Shayganfard, Mehran Abdus, Ayda Almasi-Hashiani, Amir Med Gas Res Research Article Electroconvulsive therapy (ECT) is one of the therapeutic opportunities for patients with psychological disorders when they may decline to take medication. We sought to systematically compare the anesthetic efficacy of ketamine, propofol, and dexmedetomidine for electroconvulsive therapy in treatment-resistant major depressive disorder patients. This double-blind trial enrolled treatment-resistant major depressive disorder patients (n = 85) who had been hospitalized for ECT in the Amir Kabir Hospital’s psychiatric ward (Arak, Iran). The ketamine, propofol, and dexmedetomidine groups received a dose of 0.2 μg/kg ketamine, 1.5 mg/kg propofol, and 0.8 mg/kg dexmedetomidine, respectively. In all intervention groups, 10 mL of interventional drugs was injected intravenously for 10 minutes, and in the placebo group, 10 mL of normal saline was given over the same period. The dexmedetomidine group’s blood pressure was revealed comparatively lower at all times. Dexmedetomidine-treated patients showed their marked satisfaction, while those treated with propofol had shorter recovery time, shorter seizure duration, and shorter time to achieve an Aldrete score of 9–10 and increased relaxation, and next dexmedetomidine produced deeper relaxation. Propofol could shorten recovery time and seizure duration, and enhance relaxation, while dexmedetomidine was associated with higher patient satisfaction. Considering that any anesthetic which does not shorten seizure duration may serve efficiently for ECT and that ketamine-treated patients had more prolonged seizure duration, the preferred drug can hence be considered from various angles, thereby offering anesthetic agents with highly favorable efficacy in treatment-resistant major depressive disorder patients needing ECT. The drug choice thus depends on physical conditions, underlying diseases, and psychiatrist consultation. Wolters Kluwer - Medknow 2022-12-22 /pmc/articles/PMC9979203/ /pubmed/36571375 http://dx.doi.org/10.4103/2045-9912.350860 Text en Copyright: © 2023 Medical Gas Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Research Article
Modir, Hesameddin
Mahmoodiyeh, Behnam
Shayganfard, Mehran
Abdus, Ayda
Almasi-Hashiani, Amir
Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
title Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
title_full Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
title_fullStr Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
title_full_unstemmed Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
title_short Efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
title_sort efficacy of ketamine, propofol, and dexmedetomidine for anesthesia in electroconvulsive therapy in treatment-resistant major depressive disorder patients: a double-blind randomized clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979203/
https://www.ncbi.nlm.nih.gov/pubmed/36571375
http://dx.doi.org/10.4103/2045-9912.350860
work_keys_str_mv AT modirhesameddin efficacyofketaminepropofolanddexmedetomidineforanesthesiainelectroconvulsivetherapyintreatmentresistantmajordepressivedisorderpatientsadoubleblindrandomizedclinicaltrial
AT mahmoodiyehbehnam efficacyofketaminepropofolanddexmedetomidineforanesthesiainelectroconvulsivetherapyintreatmentresistantmajordepressivedisorderpatientsadoubleblindrandomizedclinicaltrial
AT shayganfardmehran efficacyofketaminepropofolanddexmedetomidineforanesthesiainelectroconvulsivetherapyintreatmentresistantmajordepressivedisorderpatientsadoubleblindrandomizedclinicaltrial
AT abdusayda efficacyofketaminepropofolanddexmedetomidineforanesthesiainelectroconvulsivetherapyintreatmentresistantmajordepressivedisorderpatientsadoubleblindrandomizedclinicaltrial
AT almasihashianiamir efficacyofketaminepropofolanddexmedetomidineforanesthesiainelectroconvulsivetherapyintreatmentresistantmajordepressivedisorderpatientsadoubleblindrandomizedclinicaltrial